BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Zorifertinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Zorifertinib\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07551414-2300@assetmemo.bio
DTSTAMP:20261121T005555Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Zorifertinib: Phase 2 readout est. (NCT07551414)
DESCRIPTION:Zorifertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Zo
 rifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progressi
 on in NSCLC After Third-Generation EGFR-TKI\nEstimated primary completion:
  30 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zorifer
 tinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07551414
URL:https://assetmemo.bio/drug/zorifertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07361705-2300@assetmemo.bio
DTSTAMP:20261121T005555Z
DTSTART;VALUE=DATE:20280423
DTEND;VALUE=DATE:20280424
SUMMARY:Zorifertinib: Phase 1 readout est. (NCT07361705)
DESCRIPTION:Zorifertinib\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Zo
 rifertinib With Osimertinib for NSCLC With Meningeal Progression\nEstimate
 d primary completion: 23 April 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/zorifertinib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07361705
URL:https://assetmemo.bio/drug/zorifertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
